Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Loperamide molecular structure

    Loperamide Stats & Data

    NPS DataHub
    MW477.05
    FormulaC29H33ClN2O2
    CAS53179-11-6
    IUPAC4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
    SMILESClc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1
    InChIKeyRDOIQAHITMMDAJ-UHFFFAOYSA-N
    Chemical Class Phenylpiperidine

    Pharmacology

    DrugBank
    Half-life 9.1 to 14.4 hours (average 10.8 hours) Protein binding 97% State Solid Metabolism Hepatic

    Description

    One of the long-acting synthetic antidiarrheals; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.

    Mechanism of Action

    <i>In vitro</i> and animal studies show that Loperamide acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide inhibits peristaltic activity by a direct effect on the circular and longitudinal muscles of the intestinal wall. It is a non-selective calcium channel blocker and binds to opioid mu-receptors. Evidence also suggests that at higher concentrations it binds to calmodulin.

    Pharmacodynamics

    Loperamide is a synthetic anti-diarrheal indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. Loperamide is also indicated for reducing the volume of discharge from ileostomies. In man, Loperamide prolongs the transit time of the intestinal contents. It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed. Loperamide is an opioid receptor agonist and acts on the mu opioid receptors in the myenteric plexus large intestines; it does not affect the central nervous system like other opioids. It works specifically by decreasing the activity of the myenteric plexus which decreases the motility of the circular and longitudinal smooth muscles of the intestinal wall. This increases the amount of time substances stay in the intestine, allowing for more water to be absorbed out of the fecal matter. Loperamide also decreases colonic mass movements and suppresses the gastrocolic reflex.

    Absorption

    Not significantly absorbed from the gut

    Indication

    For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.

    Elimination

    Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.

    Measured Affinities

    Guide to PHARMACOLOGY

    Measured binding and functional data for loperamide, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

    Target Action Measure Value Concentration Species Source
    μ receptor OPRM1 Agonist pKi 9.28 0.525 nM Human PMID 15454210

    Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

    Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

    Toxicity

    PubChem DrugBank

    Loperamide is an over-the-counter antidiarrheal with mu-opioid agonist activity. Central nervous system opioid effects are not observed after therapeutic oral dosing because of poor bioavailability and minimal central nervous system penetration. When loperamide is taken in large doses or with other drugs that may alter its pharmacokinetic effects, such as p-glycoprotein inhibitors, loperamide produces opioid-like symptoms. These include a sensation of euphoria, miosis, central nervous system depression, and respiratory depression.

    Toxicity (DrugBank)

    Oral, mouse: LD50 = 105 mg/kg. Symptoms of overdose include constipation, drowsiness, lethargy, and nausea.

    Experience Report Analysis

    Erowid
    27 Reports
    16 Single-substance
    2001–2025 Date Range
    18 With Age Data
    4 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 16 experience reports (16 single-substance Erowid)

    16 Reports
    4 Effects Detected
    2 Positive
    1 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 16 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 2

    Euphoria 4 of 16 70%
    Stimulation 3 of 16 70%

    Adverse Effects 1

    Anxiety 3 of 16 70%
    Show 1 neutral or unclassified mention
    Auditory Effects 3 of 16

    Also reported in combinations. In the 11 Loperamide reports where another drug was taken too, 2 mention hospital, emergency services or an overdose, 1 a seizure and 0 psychosis (too few reports for percentages). In the 16 single-substance reports: 2, 0 and 0. These are not in the figures above: they cannot be put down to Loperamide alone, and a mention is not always something that happened to the writer.

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

    Median: 40.0 mg IQR: 13.5–60.0 mg n=18

    Real-World Dose Distribution

    Erowid

    From 33 of 37 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=33)

    Median: 30.0mg 25th: 12.0mg 75th: 40.0mg 90th: 76.0mg

    Form / Preparation

    Most common forms and preparations, as a share of the 21 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

    Median: 0.608 mg/kg IQR: 0.203–0.756 mg/kg n=17

    Redose Patterns

    Redosing behavior across 21 reports

    14.3% (95% interval 5 to 35 percent) Redosed
    1.2 Avg Doses
    ← Back to Loperamide